866-997-4948(US-Canada Toll Free)

Influenza A Infections - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 132 Pages


This report provides comprehensive information on the therapeutic development for Influenza A Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Influenza A Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Influenza A Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Influenza A Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Influenza A Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Influenza A Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Influenza A Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Influenza A Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 8
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Influenza A Infections Overview 11
Therapeutics Development 12
Pipeline Products for Influenza A Infections Overview 12
Pipeline Products for Influenza A Infections Comparative Analysis 13
Influenza A Infections Therapeutics under Development by Companies 14
Influenza A Infections Therapeutics under Investigation by Universities/Institutes 17
Influenza A Infections Pipeline Products Glance 18
Clinical Stage Products 18
Early Stage Products 19
Influenza A Infections Products under Development by Companies 20
Influenza A Infections Products under Investigation by Universities/Institutes 22
Influenza A Infections Companies Involved in Therapeutics Development 23
F. Hoffmann-La Roche Ltd. 23
Autoimmune Technologies, LLC 24
GlaxoSmithKline plc 25
Inovio Pharmaceuticals, Inc. 26
Vertex Pharmaceuticals Incorporated 27
Crucell N.V. 28
Hemispherx Biopharma, Inc. 29
Amarillo Biosciences, Inc. 30
SIGA Technologies, Inc. 31
Vironova AB 32
CureVac GmbH 33
PT Bio Farma 34
Viroblock S.A. 35
Innate Therapeutics Limited 36
Chimerix, Inc. 37
Theraclone Sciences, Inc. 38
Immune Targeting Systems (ITS) Ltd. 39
Sinovac Biotech Ltd. 40
Microbiotix, Inc. 41
Alios BioPharma, Inc. 42
ImmuneRegen BioSciences, Inc. 43
Vivaldi Biosciences Inc. 44
Humabs BioMed SA 45
Microgen Scientific Industrial Company for Immunobiological Medicines 46
Influenza A Infections Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Target 48
Assessment by Mechanism of Action 51
Assessment by Route of Administration 54
Assessment by Molecule Type 56
Drug Profiles 59
diridavumab - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
interferon alfa - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
FP-01 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
CR-8020 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
TCN-032 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
midodrine hydrochloride - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
VX-787 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Avian Flu Vaccine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
RG-7745 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Influenza A H7N7 vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
VIS-410 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Orvax - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
GSK-3206641-A - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
GSK-3206640A - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
H7N9 Vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Homspera - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
rintatolimod - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
interferon alfa-n3 (human leukocyte derived) - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Drug For Influenza A Infections - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
MIS-416 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Flufirvitide-3 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Nucleozin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Small Molecule For Influenza A - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ET-001 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
CR-8043 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
FI-6 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
Pam2Cys Vaccine - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
DNA Vaccine for H7N9 Universal Influenza - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
Influenza Vaccine - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Peptides for Influenza Infections - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
Gamma-Flu - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
Influenza Drug Discovery Program - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Monoclonal Antibody to Inhibit Hemagglutinin for Influenza A Virus Infection - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
Small Molecule To Inhibit Hemagglutinin For Influenza A - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
Drug For Influenza A - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
AL-18 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
MBX-2329 - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
MBX-2546 - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Fluinhibit - Drug Profile 105
Product Description 105
Mechanism of Action 105
R&D Progress 105
Drug for Influenza Virus - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
Vaccines for Influenza A H7N9 Infections - Drug Profile 107
Product Description 107
Mechanism of Action 107
R&D Progress 107
Influenza A Infections Recent Pipeline Updates 108
Influenza A Infections Dormant Projects 120
Influenza A Infections Discontinued Products 121
Influenza A Infections Product Development Milestones 122
Featured News & Press Releases 122
Oct 24, 2013: Baxter\'s Vepacel Receives CHMP Positive Opinion 122
Oct 21, 2013: NanoViricides Says Early Results Indicate that FluCide Was Extremely Safe in a non-GLP Small Animal Tox Study 122
Oct 07, 2013: NanoViricides Announces Initiation of Toxicology Study of FluCide 123
Sep 09, 2013: Theraclone Sciences Announces Universal Therapeutic Antibody for Influenza A Demonstrates Reductions in Clinical Symptoms Score and Viral Load in a Phase 2a Human Viral Challenge Study 124
Sep 09, 2013: Visterra Presents Prophylactic and Therapeutic Efficacy Data of VIS410 Against Multiple Influenza Strains with Pandemic Potential 125
Aug 26, 2013: Hemispherx Announces Biosecurity Program to Potentially Reduce Pandemic Influenza Threat 126
Aug 05, 2013: NanoViricides Signs a Non-Disclosure Agreement with the Lovelace Respiratory Research Institute for IND-enabling Efficacy Studies on FluCide and for Testing its Novel Drug Candidates against the Highly Lethal MERS Human Coronavirus 127
Oct 25, 2012: Theraclone Sciences Initiates Phase II Viral Challenge Clinical Study Of Therapeutic Antibody For Treatment Of Influenza A 127
Oct 18, 2012: Sanofi Pasteur\'s sBLA For New Four-Strain Influenza Vaccine Accepted For Review By FDA 128
Sep 17, 2012: Immune Targeting Systems Announces Positive Phase I Data For Flunisyn 129

Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 132
Disclaimer 132

List of Table


Number of Products under Development for Influenza A Infections, H1 2014 12
Number of Products under Development for Influenza A Infections Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 15
Number of Products under Development by Companies, H1 2014 (Contd..1) 16
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Development, H1 2014 19
Products under Development by Companies, H1 2014 20
Products under Development by Companies, H1 2014 (Contd..1) 21
Products under Investigation by Universities/Institutes, H1 2014 22
Influenza A Infections Pipeline by F. Hoffmann-La Roche Ltd., H1 2014 23
Influenza A Infections Pipeline by Autoimmune Technologies, LLC, H1 2014 24
Influenza A Infections Pipeline by GlaxoSmithKline plc, H1 2014 25
Influenza A Infections Pipeline by Inovio Pharmaceuticals, Inc., H1 2014 26
Influenza A Infections Pipeline by Vertex Pharmaceuticals Incorporated, H1 2014 27
Influenza A Infections Pipeline by Crucell N.V., H1 2014 28
Influenza A Infections Pipeline by Hemispherx Biopharma, Inc., H1 2014 29
Influenza A Infections Pipeline by Amarillo Biosciences, Inc., H1 2014 30
Influenza A Infections Pipeline by SIGA Technologies, Inc., H1 2014 31
Influenza A Infections Pipeline by Vironova AB, H1 2014 32
Influenza A Infections Pipeline by CureVac GmbH, H1 2014 33
Influenza A Infections Pipeline by PT Bio Farma, H1 2014 34
Influenza A Infections Pipeline by Viroblock S.A., H1 2014 35
Influenza A Infections Pipeline by Innate Therapeutics Limited, H1 2014 36
Influenza A Infections Pipeline by Chimerix, Inc., H1 2014 37
Influenza A Infections Pipeline by Theraclone Sciences, Inc., H1 2014 38
Influenza A Infections Pipeline by Immune Targeting Systems (ITS) Ltd., H1 2014 39
Influenza A Infections Pipeline by Sinovac Biotech Ltd., H1 2014 40
Influenza A Infections Pipeline by Microbiotix, Inc., H1 2014 41
Influenza A Infections Pipeline by Alios BioPharma, Inc., H1 2014 42
Influenza A Infections Pipeline by ImmuneRegen BioSciences, Inc., H1 2014 43
Influenza A Infections Pipeline by Vivaldi Biosciences Inc., H1 2014 44
Influenza A Infections Pipeline by Humabs BioMed SA, H1 2014 45
Influenza A Infections Pipeline by Microgen Scientific Industrial Company for Immunobiological Medicines, H1 2014 46
Assessment by Monotherapy Products, H1 2014 47
Number of Products by Stage and Target, H1 2014 50
Number of Products by Stage and Mechanism of Action, H1 2014 53
Number of Products by Stage and Route of Administration, H1 2014 55
Number of Products by Stage and Molecule Type, H1 2014 58
Influenza A Infections Therapeutics Recent Pipeline Updates, H1 2014 108
Influenza A Infections Dormant Projects, H1 2014 120
Influenza A Infections Discontinued Products, H1 2014 121

List of Chart


Number of Products under Development for Influenza A Infections, H1 2014 12
Number of Products under Development for Influenza A Infections Comparative Analysis, H1 2014 13
Number of Products under Development by Companies, H1 2014 14
Number of Products under Investigation by Universities/Institutes, H1 2014 17
Comparative Analysis by Clinical Stage Development, H1 2014 18
Comparative Analysis by Early Stage Products, H1 2014 19
Assessment by Monotherapy Products, H1 2014 47
Number of Products by Top 10 Target, H1 2014 48
Number of Products by Stage and Top 10 Target, H1 2014 49
Number of Products by Top 10 Mechanism of Action, H1 2014 51
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 52
Number of Products by Top 10 Route of Administration, H1 2014 54
Number of Products by Stage and Top 10 Route of Administration, H1 2014 55
Number of Products by Top 10 Molecule Type, H1 2014 56
Number of Products by Stage and Top 10 Molecule Type, H1 2014 57

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *